VEGF News and Research

RSS

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.

Combination of three technologies makes potential treatment effective against aggressive brain tumor

A drug carrier able to reach the brain, bind to an aggressive type of tumor called glioblastoma multiforme, and release a chemotherapeutic agent has been tested for the first time by Brazilian researchers.

15 Jun 2022

Study reveals the benefits of using thalidomide in patients with severe arteriovenous malformations

The same properties that caused birth defects when it was given to pregnant women, the inhibition of blood vessel formation (anti-angiogenesis), have led to an interest in thalidomide's therapeutic utility in other fields.

10 Jun 2022

Molecular target discovery opens new pathways for developing effective anti-angiogenic cancer therapy

Researchers with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute have identified a new molecular drug target that could result in new cancer drugs with fewer side effects.

20 May 2022

MAPK pathway mutations can provide “precision” treatment targets for head and neck cancer

About one-fifth of often deadly head and neck cancers harbor genetic mutations in a pathway that is key to normal cell growth, and scientists report those mutations, which enable abnormal cancer cell growth, can also make the cancer vulnerable.

28 Apr 2022

Treatment for retinal vein occlusion yields long-lasting vision gains, study shows

New research shows that a treatment for retinal vein occlusion yields long-lasting vision gains, with visual acuity remaining significantly above baseline at five years.

21 Apr 2022

Exploring strategies for successful delivery of messenger RNA therapeutics

Researchers reviewed the material properties and administration routes that could successfully deliver a messenger ribonucleic acid therapeutic agent to its targeted site.

14 Apr 2022

Curcumin released from magnetic hydrogels promotes the secretion of vascular endothelial growth factor

A finding by UC Riverside bioengineers could hasten development of lab-grown blood vessels and other tissues to replace and regenerate damaged tissues in human patients. The results are published in ACS Applied Materials and Interfaces.

6 Apr 2022

Powerhouse-pruning protein may also help make energy rapidly available for growing new blood vessels

A protein that helps keep our cell powerhouses working at a premium appears to also help make energy rapidly available when it's time to make new blood vessels.

4 Apr 2022

Unusual partners are key to making more blood vessels

Insufficient oxygen to an area like the heart or legs, called hypoxia, is a cue to our bodies to make more blood vessels, and scientists have found some unusual partners are key to making that happen.

8 Mar 2022

Researchers identify a bivalent histone-mark switch essential for angiogenesis

Defying conventional epigenomic wisdom, the non-conventional polycomb (PRC)1 variant paradoxically overwhelms the conventional PRC-mediated gene silencing in activated endothelial cells.

8 Feb 2022

SARS-CoV-2 cytokine storm inhibited by curcumin nanoparticles

In a recent study published in the journal ACS Applied Bio Materials, researchers demonstrated the inhibitory potential of curcumin-encapsulated polysaccharide nanoparticles (CUR−PS-NPs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (CoV2-SP)-stimulated cytokine storm in lung and liver epithelial cells.

8 Feb 2022

Study: Nearly 30% of people with blinding retinal disease can safely stop eye injection therapy

In a preliminary study of 106 people with "wet" age-related macular degeneration, Johns Hopkins Medicine researchers report that as many as a third of those with the blinding retinal disease may someday be able to safely stop eye injection therapy without further vision loss.

18 Jan 2022

Study identifies several proteins that protect against disease development

Inflammatory processes are associated with a large range of human diseases, including rheumatic diseases and allergies. Protein biomarkers are measurable molecules that can have a prognostic value in patients, be used to diagnose disease, or indicate severity of disease.

8 Dec 2021

Role of interferon type I-driven responses associated with disease control in COVID-19

New research suggests that treatment with type I interferons in the early stage of COVID-19 may supress disease progression by limiting SARS-CoV-2 in hosts.

1 Dec 2021

Investigation of Budesonide's mechanism of action against SARS-CoV-2

Researchers look to gain an understanding of the mechanism of action of budesonide in improving the prognosis of patients with SARS-CoV-2 infection.

1 Nov 2021

Immune cell patterns can help predict if kidney cancer patients will respond to immunotherapy

Researchers at the Francis Crick Institute, The Royal Marsden NHS Foundation Trust and UCL have found immune cell patterns within tumors that can help predict if patients with kidney cancer will respond to immunotherapy.

28 Oct 2021

Intussusceptive angiogenesis contributes to tumor growth in metastatic malignant melanoma

For the first time, researchers at the University of Gothenburg have shown that metastases in patients with malignant melanoma gain access to the circulatory system not only through the outgrowth of new blood vessel branches, but also an alternative process in which one blood vessel divide into two parallel vessels bylongitudinal splitting.

26 Oct 2021

Chilblain-like lesions and COVID-19

The ongoing COVID-19 pandemic brought about by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has also been responsible for various cutaneous manifestations. Among them, chilblain-like lesions (CLL) have been found to occur more frequently.

7 Oct 2021

Decline in SARS-CoV-2 neutralizing antibodies and unique cytokine profile in severe COVID-19 patients

A new study has focused on antibody levels and cytokine profiles of COVID-19 patients with mild symptoms, pneumonia, and severe pneumonia.

21 Sep 2021

First-in-kind kidney cancer drug developed at UTSW receives FDA approval

A first-in-kind kidney cancer drug developed from laboratory and translational studies conducted at UT Southwestern Medical Center received approval from the Food and Drug Administration, providing a new treatment for patients with familial kidney cancer.

24 Aug 2021